IQVIA’s $760 Million Acquisition of Q2 Solutions

Dechert advised Quest Diagnostics in the transaction.

Quest Diagnostics completed the sale of its ownership interest in Q2 Solutions, a global leader in central laboratory services to support clinical trials of new pharmaceuticals, to IQVIA for $760 million in an all cash transaction. The deal was announced April 1, 2021. IQVIA previously owned a 60 percent majority share and Quest Diagnostics owned a 40 percent minority share.

Quest Diagnostics (NYSE: DGX) is an American clinical laboratory. Quest Diagnostics empowers people to take action to improve health outcomes. 

The Dechert team included corporate partners Michael Darby (Picture), Christopher Field, Douglas Getter and Ken Young, counsel James Stonehill, and associates Erin O’Gurek and Paul Bennett; tax partners Edward Lemanowicz and Daniel Hawthorne, and associates George Davis and Kalina Hannsz; antitrust partner James Fishkin, counsel Beverly Ang and Michael Okkonen, and associate Delphine Strohl; cybersecurity partner Karen Neuman, and associates Madeleine White and Michael Tierney; employee benefits partner Eric Rubin; labor counsel Ian Downes; regulatory partner Susan Hendrickson; real estate special counsel Francois Quintard-Morenas; and assisted by trainee solicitor Fahwad Khan.

Involved fees earner: Beverly Ang – Dechert; Paul Bennett IV – Dechert; Michael Darby – Dechert; George Davis – Dechert; Ian Downes – Dechert; Christopher Field – Dechert; James Fishkin – Dechert; Douglas Getter – Dechert; Kalina Hannsz – Dechert; Daniel Hawthorne – Dechert; Susan Hendrickson – Dechert; Edward Lemanowicz – Dechert; Karen Neuman – Dechert; Michael Okkonen – Dechert; Erin O’Gurek – Dechert; Francois Quintard-Morenas – Dechert; Eric Rubin – Dechert; James Stonehill – Dechert; Delphine Strohl – Dechert; Michael Tierney – Dechert; Madeleine White – Dechert; Kenneth Young – Dechert;

Law Firms: Dechert;

Clients: Quest Diagnostics;

Print Friendly, PDF & Email

Author: Martina Bellini